{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:32:52Z","timestamp":1792899172710,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-TR-128"],"award-info":[{"award-number":["SFB CRC-TR-128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-1292"],"award-info":[{"award-number":["SFB CRC-1292"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1080"],"award-info":[{"award-number":["SFB 1080"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR 355"],"award-info":[{"award-number":["SFB\/TRR 355"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017694","name":"Hermann and Lilly Schilling Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.medj.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:33:41Z","timestamp":1730975621000},"page":"100529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis"],"prefix":"10.1016","volume":"6","author":[{"given":"Maria","family":"Protopapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Schraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Steenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-3655","authenticated-orcid":false,"given":"Stefan","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.10.006_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.006_bib2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II","volume":"28","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2024.10.006_bib3","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.10.006_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105400","article-title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","volume":"82","author":"Baker","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2024.10.006_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after\u00a0rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.medj.2024.10.006_bib6","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.006_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/13524585231206218","article-title":"Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab","volume":"30","author":"Beigneux","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2024.10.006_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neurol.2021.06.007","article-title":"Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study","volume":"178","author":"Rigal","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.medj.2024.10.006_bib9","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.medj.2024.10.006_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","article-title":"Neutropenia after rituximab treatment: new insights on a late complication","volume":"19","author":"Wolach","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.medj.2024.10.006_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","article-title":"Rituximab-associated neutropenia","volume":"47","author":"Dunleavy","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.medj.2024.10.006_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature","volume":"409","author":"Zanetta","year":"2020","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.medj.2024.10.006_bib13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00115-023-01507-2","article-title":"[Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?]","volume":"94","author":"Hess","year":"2023","journal-title":"Nervenarzt"},{"key":"10.1016\/j.medj.2024.10.006_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1941874420936438","article-title":"Severe Delayed-Onset Neutropenia Induced by Ocrelizumab","volume":"11","author":"Baird-Gunning","year":"2021","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.medj.2024.10.006_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.medj.2024.10.006_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.10.006_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2024.10.006_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.medj.2024.10.006_bib19","first-page":"361","article-title":"High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation","volume":"89","author":"Cairoli","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.medj.2024.10.006_bib20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.medj.2024.10.006_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ajh.21420","article-title":"Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma","volume":"84","author":"Lai","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.medj.2024.10.006_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.10.006_bib23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-008-9049-z","article-title":"Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of\u00a0granulopoiesis","volume":"25","author":"Tesfa","year":"2008","journal-title":"Med. Oncol."},{"key":"10.1016\/j.medj.2024.10.006_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.msard.2013.08.001","article-title":"Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica","volume":"3","author":"Plate","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2024.10.006_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.msard.2017.12.005","article-title":"Severe neutropenia after rituximab-treatment of multiple sclerosis","volume":"20","author":"Rissanen","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2024.10.006_bib30","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1177\/1352458518765677","article-title":"Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder","volume":"24","author":"Biotti","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2024.10.006_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102019","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","volume":"41","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2024.10.006_bib27","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1007\/s10072-021-05357-1","article-title":"Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient","volume":"42","author":"Marrodan","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.medj.2024.10.006_bib26","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1007\/s10072-021-05379-9","article-title":"Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.medj.2024.10.006_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nrl.2021.01.010","article-title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","volume":"38","author":"Alba Su\u00e1rez","year":"2021","journal-title":"Neurologia (Engl Ed)."},{"key":"10.1016\/j.medj.2024.10.006_bib31","article-title":"Myeloid maturation arrest and severe late-onset neutropenia following ocrelizumab therapy in a patient with multiple sclerosis: A case report and review of the literature","volume":"1","author":"Kermode","year":"2021","journal-title":"Neuroimmunol. Rep."},{"key":"10.1016\/j.medj.2024.10.006_bib42","article-title":"A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy","volume":"16","author":"Alabdulqader","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.medj.2024.10.006_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.medj.2024.10.006_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.medj.2024.10.006_bib34","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.medj.2024.10.006_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2024.10.006_bib36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-019-0521-4","article-title":"GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis","volume":"25","author":"Galli","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.10.006_bib37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1084\/jem.194.7.873","article-title":"Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis","volume":"194","author":"McQualter","year":"2001","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2024.10.006_bib38","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000215","article-title":"Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy","volume":"3","author":"Rust","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2024.10.006_bib39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","article-title":"ROR\u03b3t drives production of the cytokine GM-CSF in helper T\u00a0cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2024.10.006_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1742-2094-8-73","article-title":"Lymph node-derived donor encephalitogenic CD4+ T\u00a0cells in C57BL\/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet","volume":"8","author":"Cravens","year":"2011","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.medj.2024.10.006_bib41","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1038\/ncomms6056","article-title":"Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells","volume":"5","author":"Hartmann","year":"2014","journal-title":"Nat. Commun."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:58:47Z","timestamp":1778921927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024004045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666634024004045"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.006","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100529"}}